tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), CytomX Therapeutics (CTMX) and Bausch + Lomb Corporation (BLCO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agenus (AGENResearch Report), CytomX Therapeutics (CTMXResearch Report) and Bausch + Lomb Corporation (BLCOResearch Report).

Agenus (AGEN)

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Agenus today and set a price target of $8.00. The company’s shares closed last Friday at $1.60, close to its 52-week low of $1.30.

According to TipRanks.com, Bodnar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -6.5% and a 34.6% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Gracell Biotechnologies, and TransCode Therapeutics.

Currently, the analyst consensus on Agenus is a Strong Buy with an average price target of $8.08.

See today’s best-performing stocks on TipRanks >>

CytomX Therapeutics (CTMX)

In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Hold rating on CytomX Therapeutics. The company’s shares closed last Friday at $1.72.

According to TipRanks.com, Kapoor is a 2-star analyst with an average return of 0.6% and a 42.9% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as TC Biopharm (Holdings) Plc Sponsored ADR, Rani Therapeutics Holdings, and Century Therapeutics.

CytomX Therapeutics has an analyst consensus of Hold, with a price target consensus of $2.70, a 64.6% upside from current levels. In a report issued on June 30, Mizuho Securities also maintained a Hold rating on the stock with a $2.00 price target.

Bausch + Lomb Corporation (BLCO)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Bausch + Lomb Corporation, with a price target of $22.00. The company’s shares closed last Friday at $20.07.

According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of -29.1% and a 25.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Greenwich LifeSciences.

Bausch + Lomb Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $20.86, which is a 2.3% upside from current levels. In a report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $23.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AGEN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles